These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Maximal bladder capacity is a positive predictor of response to desmopressin treatment in patients with MS and nocturia. Zahariou A; Karamouti M; Karagiannis G; Papaioannou P Int Urol Nephrol; 2008; 40(1):65-9. PubMed ID: 17610036 [TBL] [Abstract][Full Text] [Related]
3. Pathophysiological aspects of nocturia in a danish population of men and women age 60 to 80 years. Bing MH; Moller LA; Jennum P; Mortensen S; Lose G J Urol; 2007 Aug; 178(2):552-7. PubMed ID: 17570415 [TBL] [Abstract][Full Text] [Related]
4. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Valiquette G; Herbert J; Maede-D'Alisera P Arch Neurol; 1996 Dec; 53(12):1270-5. PubMed ID: 8970454 [TBL] [Abstract][Full Text] [Related]
5. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Van Kerrebroeck P; Andersson KE Neurourol Urodyn; 2014 Apr; 33 Suppl 1():S2-5. PubMed ID: 24729150 [TBL] [Abstract][Full Text] [Related]
7. Perspectives on urological care in multiple sclerosis patients. Moussa M; Abou Chakra M; Papatsoris AG; Dabboucy B; Hsieh M; Dellis A; Fares Y Intractable Rare Dis Res; 2021 May; 10(2):62-74. PubMed ID: 33996350 [TBL] [Abstract][Full Text] [Related]
9. Detrusor overactivity persisting at night and preceding nocturia in patients with overactive bladder syndrome: a nocturnal cystometrogram and polysomnogram study. Krystal AD; Preud'homme XA; Amundsen CL; Webster GD J Urol; 2010 Aug; 184(2):623-8. PubMed ID: 20639027 [TBL] [Abstract][Full Text] [Related]
10. Management of Nocturia and Nocturnal Polyuria. Weiss JP; Everaert K Urology; 2019 Nov; 133S():24-33. PubMed ID: 31586470 [TBL] [Abstract][Full Text] [Related]
11. Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study. Rovner ES; Raymond K; Andruczyk E; Juul KV Low Urin Tract Symptoms; 2018 Sep; 10(3):221-230. PubMed ID: 28560762 [TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Leippold T; Reitz A; Schurch B Eur Urol; 2003 Aug; 44(2):165-74. PubMed ID: 12875934 [TBL] [Abstract][Full Text] [Related]
13. [Urodynamic changes in patients with obstructive sleep apnea-hypopnea syndrome and nocturnal polyuria]. Hu K; Tu ZS; Lü SQ; Li QQ; Chen XQ Zhonghua Jie He He Hu Xi Za Zhi; 2011 Mar; 34(3):182-6. PubMed ID: 21569684 [TBL] [Abstract][Full Text] [Related]
14. Lower urinary tract dysfunction in patients with multiple sclerosis. Panicker JN; Fowler CJ Handb Clin Neurol; 2015; 130():371-81. PubMed ID: 26003255 [TBL] [Abstract][Full Text] [Related]
15. Desmopressin and nocturnal voiding dysfunction: Clinical evidence and safety profile in the treatment of nocturia. Chung E Expert Opin Pharmacother; 2018 Feb; 19(3):291-298. PubMed ID: 29376448 [TBL] [Abstract][Full Text] [Related]
16. Influence of type of nocturia and lower urinary tract symptoms on therapeutic outcome in women treated with desmopressin. Jeong JY; Kim SJ; Cho HJ; Hong SH; Lee JY; Hwang TK; Kim SW Korean J Urol; 2013 Feb; 54(2):95-9. PubMed ID: 23549374 [TBL] [Abstract][Full Text] [Related]
17. Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms. Bae WJ; Bae JH; Kim SW; Chung BH; Kim JH; Kim CS; Lee HM; Lee KS; Yoo TK; Kim SI; Byun SS; Lee JY J Urol; 2013 Jul; 190(1):180-6. PubMed ID: 23357213 [TBL] [Abstract][Full Text] [Related]
18. Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. Zachariou A; Filiponi M; Baltogiannis D; Giannakis J; Dimitriadis F; Tsounapi P; Takenaka A; Sofikitis N Can J Urol; 2017 Dec; 24(6):9107-9113. PubMed ID: 29260636 [TBL] [Abstract][Full Text] [Related]